Keith Flaherty, MD
Enriched profileDirector of Clinical Research · Massachusetts General Hospital
Keith Flaherty is Director of Clinical Research at Massachusetts General Hospital. OpenAlex indexes 1,807 publications with 122,946 citations (h-index 147); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the FindMyKOL directory.
Data verified 26 Oct 2026
Overview
Updated 27 Oct 2026
Keith Flaherty, MD, is Director of Clinical Research at Massachusetts General Hospital. The public record shows 1,807 publications with 122,946 citations (h-index 147), centered on Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 1 companies, 2 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Melanoma and MAPK Pathways
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 82 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 512.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 26 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Sponsor: Massachusetts General Hospital
- Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Industry payments
Updated 26 Oct 2026
1 company reported payments to CMS in program years 2021–2022. These are public disclosures, not judgments. The latest:
- Clovis Oncology, Inc.Program year20223 payments$48,750openpaymentsdata.cms.gov ↗
- Clovis Oncology, Inc.Program year20215 payments$257,030openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%B-Raf serine-threonine kinase (BRAF) inhibitors50%Braftovi100%Part D<11 patientsMitogen-activated protein kinase (MEK) inhibitors50%Mektovi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 26 Oct 2026
2 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN
Dana-Farber Cancer Inst
FY2026$2,272,446UM1CA186709 - Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
Dana-Farber Cancer Inst
FY2025$2,074,014UM1CA186709 - DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN
Dana-Farber Cancer Inst
FY2025$194,240UM1CA186709
Congress activity
Updated 26 Oct 2026
232 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Comprehensive genomic profiling of matched ctDNA and tissue from patients with four common cancers enrolled to the NCI-MATCH trial.
ASCO Annual Meeting
ASCO2026Co-author - Abstract B034: Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 26 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
Journal of clinical oncology
Clinical Trial2026 - Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.
Nature communications
Article2026
Most-cited works
by citation count (OpenAlex)- 01Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationArticle7,722 citations2011
- 02Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seqArticle4,926 citations2016
- 03Final Version of 2009 AJCC Melanoma Staging and ClassificationArticle4,608 citations2009
- 04Inhibition of Mutated, Activated BRAF in Metastatic MelanomaArticle3,564 citations2010
- 05Genomic Classification of Cutaneous MelanomaArticle3,144 citations2015
Network
Updated 26 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 26 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/keith-flaherty-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 26 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Johns Hopkins University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗ - Board certification: Medical Oncology
American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Harvard Medical School
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗ - Associate member
Broad Institute of MIT and Harvard
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗ - Founding member
Mass General Brigham
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtech.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mtrudnak.podbean.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
Andrew Zhu, MD, PhD
Massachusetts General Hospital
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Omid Hamid, MD
The Angeles Clinic and Research Institute
Walter Urba, MD
Providence Cancer Institute